<DOC>
	<DOCNO>NCT01620970</DOCNO>
	<brief_summary>Salvage chemotherapy advance urothelial cancer ( UC ) yield suboptimal response rate 15-40 % , median progression-free survival 2-4 month median overall survival 6 month . A rationale target angiogenesis UC support preclinical evidence early signal clinical activity anti-VEGF TKI demonstrate group use pazopanib . Despite activity , progression inevitably occur mechanism determine resistance conventional anti-angiogenic agent investigation . PF-03446962 ( Pfizer Inc ) novel fully human monoclonal antibody ( mAb ) ALK1 dose-dependent antiangiogenic activity demonstrate nonclinical study chimera mouse model bear human tumor xenograft . The investigator suggest PF-03446962 may increase current result patient advanced urothelial cancer fail upfront chemotherapy due mechanism action . Due lack reliable reproducible predictor response well imaging tool assess tumor response , trial provide incorporation 18FDG-PET/CT contrast-enhanced ultrasound stage evaluate response urothelial cancer , together standard image modality ( RECIST criterion ) . Blood tissue sample collect translational purpose .</brief_summary>
	<brief_title>PF-03446962 Relapsed Refractory Urothelial Cancer</brief_title>
	<detailed_description>This open-label , single arm , non randomise , phase II proof-of-concept study monoclonal antibody TGF-beta receptor ALK1 ( PF03446962 ) patient urothelial cancer relapsing/progressing first line chemotherapy . The study plan accord Simon 's Optimal two-stage design . The primary endpoint proportion patient progression-free 2-months . A 2-month PFS rate 50 % promising , 70 % rate promising . In stage 1 , 21 evaluable patient accrue . If 12 patient least progression-free 2 month , enrollment extend 2nd stage 24 patient . If , total 45 patient , 27 least progression-free 2 month , treatment declare worthy investigation . Maximum overall accrual 45 patient . Type I type II error rate set 10 % level .</detailed_description>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age &gt; 18 year . ECOG Performance status 0 1 . Life expectancy least 12 week . Measurable disease criterion ( RECIST v1.1 ) . Histological diagnosis urothelial cancer . Locally advanced metastatic disease . Failure least 1 prior chemotherapy regimen metastatic disease . Neoadjuvant/adjuvant therapy consider relapse occur within 6 month last cycle chemotherapy . Adequate bone marrow , liver renal function requirement , conduct within 7 day prior screen . Cardiovascular CNS disease . Previously untreated CNS metastasis . Active Hepatitis B , C , HIV infection . Pregnant breastfeeding patient . GI abnormalities clinical condition high risk bleeding . Substance abuse condition may interfere patient 's participation study evaluation study result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Transitional Cell Carcinoma</keyword>
	<keyword>Metastatic disease</keyword>
	<keyword>Bladder tumor , Recurrent</keyword>
	<keyword>Angiogenesis</keyword>
	<keyword>PF03446962</keyword>
	<keyword>Transforming growth factor beta</keyword>
	<keyword>Activin receptor like kinase 1</keyword>
	<keyword>Monoclonal Antibody</keyword>
	<keyword>Locally advanced metastatic disease</keyword>
	<keyword>Failure one platinum-based chemotherapy</keyword>
	<keyword>Measurable disease</keyword>
</DOC>